Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Sara Valpione, Matteo S Carlino, Johanna Mangana, Meghan J Mooradian, Grant McArthur, Dirk Schadendorf, Axel Hauschild, Alexander M Menzies, Ana Arance, Paolo A Ascierto, AnnaMaria Di Giacomo, Francesco de Rosa, James Larkin, John J Park, Simone M Goldinger, Ryan J Sullivan, Wen Xu, Elisabeth Livingstone, Michael Weichenthal, Rajat Rai Show all
EUROPEAN JOURNAL OF CANCER | ELSEVIER SCI LTD | Published : 2018
BACKGROUND: Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse retrospectively outcomes for patients retreated with BRAF-directed therapy. PATIENTS AND METHODS: One hundred sixteen metastatic melanoma patients who received BRAFi-based therapy and, after a break, were rechallenged with BRAFi ± MEKi at 14 centres in Europe, US and Australia were studied, respectively. Response rate (RR), overall survival (OS) and progression-free ..View full abstract
The authors are grateful to Prof. Simone Mocellin for the independent statistical review of the manuscript. The authors are grateful to Prof. Reinhard Dummer, Prof Keith Flaherty and Prof Michele Maio for their collaboration. S.V. would like to thank Dr. Tara Gangadhar for her advice. S.V. was supported by the ESMO Clinical Research Fellowship with the aid of a grant from Novartis (ESMO Clinical Research Fellowship 2015-2016). Any views, opinions, findings, conclusions or recommendations expressed in this material are those solely of the author(s) and do not necessarily reflect those of ESMO or Novartis.